关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025 年 8 月 28 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) -双鸽集团有限公司 2025年8月28日 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 济民健康管理股份有限公司: 李仙玉: nda dri 张雪琴: 李慧慧: 李丽莎: 田云飞: t 别 涌: 2025 年 8 月 28 日 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 1 ...

Market Overview - The medical device sector experienced a slight decline of 0.08% on August 28, with Tuo Jing Life leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Top Performers - Fu Rui Co., Ltd. (300049) saw a significant increase of 15.35%, closing at 65.02 with a trading volume of 461,000 shares and a transaction value of 2.915 billion [1] - Ji Min Health (603222) rose by 9.96%, closing at 11.04 with a trading volume of 1.27 million shares [1] - Hua Kang Clean (301235) increased by 6.84%, closing at 34.38 with a trading volume of 64,100 shares [1] Underperformers - Tuo Jing Life (300642) declined by 5.41%, closing at 27.97 with a trading volume of 263,500 shares and a transaction value of 735 million [2] - Xiang Sheng Medical (688358) fell by 4.97%, closing at 32.12 with a trading volume of 37,700 shares [2] - Tian Zhi Hang (688277) decreased by 4.77%, closing at 18.38 with a trading volume of 261,600 shares [2] Capital Flow - The medical device sector saw a net outflow of 1.115 billion from institutional investors, while retail investors contributed a net inflow of 965 million [2][3] - The top net inflows from retail investors were observed in Fu Rui Co., Ltd. (300049) with 30.3 million and Ji Min Health (603222) with 11.5 million [3]

Market Overview - The Shanghai Composite Index fell by 1.76% on August 27, with only one industry, communication, showing an increase of 1.66%. The beauty care and real estate sectors experienced the largest declines, down 3.86% and 3.51% respectively. The pharmaceutical and biotechnology sector also saw a decrease of 2.73% [1]. Capital Flow Analysis - The main capital outflow from both markets totaled 129.75 billion yuan, with all sectors under the Shenwan classification experiencing net outflows. The computer industry led with a net outflow of 16.31 billion yuan, followed by the pharmaceutical and biotechnology sector with a net outflow of 12.33 billion yuan. Other sectors with significant outflows included electronics, automotive, and machinery equipment [1]. Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector had 474 stocks, with 36 gaining and 438 losing value. Five stocks hit the daily limit up, while one stock hit the limit down. The sector saw a net outflow of 12.33 billion yuan, with 114 stocks experiencing net inflows, and 28 stocks seeing outflows exceeding 100 million yuan [2]. Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Jimin Health: +9.97% with a net inflow of 118.04 million yuan - Nanxin Pharmaceutical: +20.00% with a net inflow of 109.05 million yuan - BGI Genomics: +0.09% with a net inflow of 106.94 million yuan [2]. Major Outflows in Pharmaceutical Sector - The stocks with the largest net outflows included: - Hengrui Medicine: -3.45% with a net outflow of 901.64 million yuan - WuXi AppTec: -1.45% with a net outflow of 482.18 million yuan - Guangsheng Tang: -10.32% with a net outflow of 378.57 million yuan [3].

Group 1 - The core viewpoint of the news is that Jimin Health has experienced a significant stock price increase, reaching a limit up of 9.97% on August 27, with a trading price of 10.04 yuan per share and a total market capitalization of 5.272 billion yuan [1] - Jimin Health Management Co., Ltd. is primarily engaged in medical health services, medical devices, and chemical pharmaceuticals, with over 30 years of business history and leading positions in safety injection and puncture devices both domestically and internationally [1] - The company has established production bases in Zhejiang, Shanghai, and Spain, and owns six wholly-owned or controlled subsidiaries, along with two general hospitals actively expanding into the health industry [1] Group 2 - As of June 30, Jimin Health had 28,100 shareholders, with an average of 18,700 circulating shares per shareholder [2] - For the first half of 2025, Jimin Health reported operating revenue of 366 million yuan, a year-on-year decrease of 21.30%, and a net profit attributable to shareholders of -52.6959 million yuan, a year-on-year decrease of 307.10% [2]

济民健康管理股份有限公司: 关于济民健康管理股份有限公司 股票交易异常波动的征询函的回函 股票交易异常波动的征询函的回函 本公司持有济民健康管理股份有限公司 24. 37%的股份,为济民健康管理股 份有限公司控股股东。 本公司于 2025 年 8 月 26 日收到你公司发来的《关于济民健康管理股份有 限公司股票交易异常波动的征询函》,现就你公司征询事项回复如下: 一、本公司不涉及你公司的应披露而未披露的重大信息,不存在针对你公司 的重大资产重组、发行股份、上市公司收购、债务重组、业务重组、资产剥离和 资产注入等重大事项。 二、无其他重大事项。 (以下无正文) 此页无正文,为《关于济民健康管理股份有限公司股票交易异常波动的征询函的 回函》之盖章页) 双鸽集团有限公司。 2025年8月26日/ 关于济民健康管理股份有限公司 济民健康管理股份有限公司: 本家族成员直接持有济民健康管理股份公司(以下简称"公司")股份 7,727.70 万股,占公司总股本的 14.72%,并持有公司控股股东双鸽集团有限公 司 100%的股权和法人股东台州市梓铭贸易有限公司 100%的股权，为公司实际控 制人。 本家族全体成员于 202 ...

证券代码：603222 证券简称：济民健康 公告编号：2025-041 济民健康管理股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 济民健康管理股份有限公司（以下简称"公司"）股票于 2025 年 8 月 22 日、 8 月 25 日、8 月 26 日连续三个交易日内收盘价格跌幅偏离值累计达到 20%，根据 《上海证券交易所交易规则》的相关规定，属于股票交易异常波动。 二、公司关注并核实的相关情况 ●公司股票交易于2025年8月22日、8月25日、8月26日连续三个交易日内收盘 价格跌幅偏离值累计超过20%，属于《上海证券交易所交易规则》规定的股票交易 异常波动情形。 ●经公司自查并书面征询控股股东及实际控制人，截至本公告披露日，公司 不存在应披露而未披露的重大事项。 ●公司敬请广大投资者注意二级市场交易风险、经营业绩风险，敬请广大投 资者理性决策，审慎投资。 一、股票交易异常波动的具体情况 针对股票交易异常波动情况，公司对有关事项进行了核查，现将有关情况说 明如 ...

济民健康(603222)今日下跌7.68%，全天换手率19.33%，成交额9.45亿元，振幅6.25%。龙虎榜数据显 示，营业部席位合计净卖出1778.77万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-7.30%上榜，营业部席位合计净卖出1778.77万元。 济民健康8月26日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 广发证券股份有限公司南京汉中路证券营业部 | 3164.12 | | | 买二 | 国泰海通证券股份有限公司总部 | 981.70 | | | 买三 | 中国银河证券股份有限公司烟台证券营业部 | 876.64 | | | 买四 | 东方财富证券股份有限公司拉萨团结路第一证券营业部 | 868.13 | | | 买五 | 首创证券股份有限公司长沙滨江路证券营业部 | 836.40 | | | 卖一 | 浙商证券股份有限公司杭州五星路证券营业部 | | 2267.34 | | 卖二 | 中信证券股份有限公司浙江分公司 | 1929.66 | | - ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]

Group 1: 康希诺 (CanSino) - The company reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26% [1] - The net profit attributable to shareholders was a loss of 13.49 million yuan, significantly narrowing from a loss of 225 million yuan in the same period last year, a reduction of 94.02% [1] - Sales revenue from two types of combined meningococcal vaccines reached approximately 364 million yuan, up 38.43% year-on-year [1] Group 2: 万泰生物 (Wantai Bio) - The company reported a revenue of 844 million yuan for the first half of 2025, a year-on-year decrease of 38.25% [2] - The net profit attributable to shareholders turned into a loss of 144 million yuan, compared to a profit in the same period last year [2] - The revenue decline was attributed to market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine age group, leading to lower-than-expected sales [2] Group 3: 济民健康 (Jimin Health) - The company reported a revenue of 366 million yuan for the first half of 2025, a year-on-year decrease of 21.30% [3] - The net profit was a loss of approximately 52.70 million yuan, compared to a profit of 25.44 million yuan in the same period last year [3] - The stock price saw a cumulative increase of 53.78% from August 13 to August 19, with a trading halt on August 20, indicating potential market overreaction [3] Group 4: ST诺泰 (ST Novartis) - The company reported a revenue of approximately 1.048 billion yuan for the first half of 2025, a year-on-year increase of 26.07% [4] - The net profit attributable to shareholders was approximately 310 million yuan, an increase of 36.49% year-on-year [4] - The revenue growth was primarily driven by significant sales increases in peptide raw materials, particularly GLP-1 related products [4] Group 5: 三博脑科 (Sanbo Brain Science) - The shareholder TBP3Doctors (HK) Limited plans to reduce its holdings by up to approximately 6.09 million shares, accounting for 3% of the total share capital [5] - The reduction will occur through centralized bidding and block trading within three months after the announcement [5] - The shareholder's decision to reduce holdings may signal a lack of confidence in the company's future development prospects [5]

Group 1 - The innovative drug concept stocks are experiencing a downturn, with multiple companies such as Guangshengtang, Yuandong Biological, Yangguang Nuohuo, Haitai Biological, Rejing Biological, Kailaiying, Lifang Pharmaceutical, and Jimin Health seeing declines of over 5% [1]